Skip to search formSkip to main contentSkip to account menu

NY-ESO-1 peptide vaccine

Known as: ESO-1 Peptide Vaccine, NY-ESO-1 peptide 
A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1), an antigen found in normal testis and… 
National Institutes of Health

Related topics

Related topics

3 relations
Antigen SensitizationNCIt Antineoplastic Agent TerminologyNY-ESO-1 Protein Vaccine Plus Montanide ISA-51 VG

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
Blockade of inhibitory signals mediated by cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) has been shown to enhance T cell… 
Highly Cited
2007
Highly Cited
2007
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer
NY-ESO-1 is a “cancer-testis” antigen expressed in epithelial ovarian cancer (EOC) and is among the most immunogenic tumor… 
Review
2006
Review
2006
NY-ESO-1: review of an immunogenic tumor antigen.
Highly Cited
2006
Highly Cited
2006
Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura
Purpose: The DNA methylation paradox, manifested as derepression of cancer-testis antigens, and silencing of tumor suppressors… 
Highly Cited
2005
Highly Cited
2005
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.
The presence of a metaphase cytogenetic abnormality (CA) is the key negative predictor of outcome in patients with multiple… 
Highly Cited
2003
Highly Cited
2003
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
Cancer-testis (CT) antigens are expressed in a variety of cancers, but not in normal adult tissues, except for germ cells of the… 
Highly Cited
2002
Highly Cited
2002
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.
The cancer-testis antigen NY-ESO-1 is one of the most promising candidates for generic vaccination of cancer patients. Here we… 
Highly Cited
2001
Highly Cited
2001
CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production
NY-ESO-1 is a tumor-specific shared antigen with distinctive immunogenicity. Both CD8+ T cells and class-switched Ab responses… 
Highly Cited
2000
Highly Cited
2000
Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL1
Expression of NY-ESO-1 in a high proportion of different human tumors makes this protein a very attractive vaccine target. NY-ESO… 
Highly Cited
2000
Highly Cited
2000
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.
NY-ESO-1, a member of the cancer-testis family of antigens, is expressed in a subset of a broad range of different human tumor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)